Figure 1From: Concurrent gemcitabine and 3D radiotherapy in patients with stage III unresectable non-small cell lung cancerSurvival of 318 patients treated with gemcitabine and 3D concurrent radiotherapy. a. Median Progression Free Survival was 15.5 months (95% CI., 12.9-18.1). b. Median Overall Survival was 24.6 months (95% CI., 21.0-28.1) with a 5-year survival of 26%.Back to article page